PILOT for The Precision Exercise Regimen for Cancer Care (PERCC) Study
This study is designed to evaluate whether a precision exercise regimen is feasible to implement within cancer populations, specifically stage II-III primary lung cancer patients receiving multimodal therapy, and delivered through telehealth.
Checked against the public recordLast updated Feb 3, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- University of Utah
- Interventions being studied
- Other: Precision Exercise Regimen for Cancer Care (PERCC)
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Ages 18 and older at time of diagnosis * Patient diagnosed with stage II and III non-small cell lung cancer (NSCLC) * Patient receives either neoadjuvant chemotherapy or immunotherapy and surgery * Patient able to follow direction and complete questionnaires in English or Spanish * Patient agrees to complete the PERCC intervention Exclusion Criteria: * Morbidly obese (BMI \>40 kg/m2 ) or anorexic (BMI \<17.5 kg/m2 ) * Abnormalities on screening physical exam per study physicians or physical therapist to contraindicate participation in exercise program compliance * Alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by NCCN Distress Thermometer) * Patient scheduled to receive single modality cancer treatment (unimodal therapy), scheduled to begin treatment within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of Texas Medical Branch at GalvestonGalveston, Texas
- Huntsman Cancer InstituteSalt Lake City, Utah
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 3, 2026. Always confirm current availability with the study team.